Turtle Cameron

Turtle Cameron is listed in filings as Chief Executive Officer at Spyre Therapeutics, Inc.. This profile follows SEC Form 4 activity through Jun 3, 2026, including sale activity. Recent filings connect the profile to Spyre Therapeutics, Inc. (SYRE) and Damora Therapeutics, Inc. (DMRA). The current snapshot covers public activity from Dec 3, 2025 to Jun 3, 2026. Reported amounts are shown as $119.5K to $3.2K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.